Preserving residual renal function in peritoneal dialysis: Volume or biocompatibility

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2620-2622

  Davies, Simon J ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID; GLUCOSE DEGRADATION PRODUCT;

BIOCOMPATIBILITY; HUMAN; HYPERVOLEMIA; KIDNEY FUNCTION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW;

BIOCOMPATIBLE MATERIALS; BLOOD VOLUME; DIALYSIS SOLUTIONS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS;

EID: 69249122373     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp313     Document Type: Review

References (22)

1. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
2. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053
3. McKane W, Chandna SM, Tattersall JE et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61: 256-265
4. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
5. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
6. Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13: 962-968
7. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-1302
8. Termorshuizen F, Dekker FW, van Manen JG et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061-1070
9. Misra M, Vonesh E, Churchill DN et al. Preservation of glomerular filtration rate on dialysis when adjusted for patient dropout. Kidney Int 2000; 57: 691-696
10. Gunal AI, Duman S, Ozkahya M et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 588-593
11. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191
12. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63: 1556-1563
13. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344
14. Davies SJ, Garcia Lopez E, Woodrow G et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23: 2982-2988
15. TranaeusA. The Bicarbonate/Lactate Study Group.Along-termstudy of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. Perit Dial Int 2000; 20: 516-523
16. le Poole CY, Welten AG, Weijmer MC et al. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25(Suppl 3): S64-S68
17. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94
18. Szeto CC, Chow KM, Lam CW et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559
19. Choi HY, Kim DK, Lee TH et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008; 28: 174-182
20. Kim SG, Kim S, Hwang YH et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).PeritDial Int 2008; 28(Suppl 3): S117-S122
21. Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206
22. Weiss L, Stegmayr B, Malmsten G et al. Biocompatibility and tolerability of a purely bicarbonatebuffered peritoneal dialysis solution. Perit Dial Int 2009; 29